薰衣草地上部分的桉烷型倍半萜类化合物及其抗胰腺癌活性。
Eudesmane-type sesquiterpenoids from the aerial parts of Artemisia lavandulaefolia and their anti-pancreatic cancer activities.
发表日期:2023 Sep 28
作者:
Lin-Fen Ding, Guo-Xian Hu, Yu-Yao Liu, Qiu-Hua Wang, Zhang-Juan Li, Meng-Xia Shen, Gui-Fa Zhu, Xing-De Wu, Jia Su
来源:
PHYTOCHEMISTRY
摘要:
从薰衣草地上部分的 95% 乙醇提取物中分离出五种未描述的桉树倍半萜类化合物(青蒿素 A-E)和一种未描述的重排桉树倍半萜类化合物(青蒿素 F),以及十种已知化合物。未描述的化合物的结构和构型主要通过光谱分析和单晶X射线衍射分析来阐明。在所有分离的化合物中,青蒿素 F 对 PANC-1 胰腺癌细胞表现出抑制活性,IC50 为 9.69 ± 2.39 μM。 Artemilavanin F 通过诱导 G2/M 细胞周期停滞和细胞周期蛋白依赖性激酶下调和活性氧积累介导的细胞凋亡来抑制 PANC-1 细胞增殖。此外,青蒿素 F 抑制 PANC-1 细胞的集落形成、细胞迁移和球体形成,表明 PANC-1 细胞的干细胞样表型受到抑制。进一步的结果证实,青蒿素 F 可以抑制 Bmi1、CD44、CD133 等癌症干细胞标志物的表达。青蒿素 F 可以抑制 N-钙粘蛋白和 Oct-4 等上皮间质转化 (EMT) 标志物的表达,表明青蒿素 F 在治疗癌症方面具有潜力。预防转移。版权所有 © 2023 Elsevier Ltd. 保留所有权利。
Five undescribed eudesmane sesquiterpenoids, artemilavanins A-E, and one undescribed rearranged eudesmane sesquiterpenoid, artemilavanin F, were isolated from the 95% ethanol extract of the aerial parts of Artemisia lavandulaefolia DC., along with ten known compounds. The structures and configurations of undescribed compounds were mainly elucidated by spectroscopic analyses and single-crystal X-ray diffraction analysis. Among all isolated compounds, artemilavanin F exhibited inhibitory activity on PANC-1 pancreatic cancer cells with IC50 of 9.69 ± 2.39 μM. Artemilavanin F inhibited PANC-1 cell proliferation by induction of G2/M cell cycle arrest and apoptosis mediated by downregulation of cyclin-dependent kinases and accumulation of reactive oxygen species. Moreover, artemilavanin F inhibited the colony formation, cell migration and sphere formation of PANC-1 cells, indicating the suppression of stem-cell-like phenotype of PANC-1 cells. Further results confirmed that the expression of cancer stem cell markers such as Bmi1, CD44, CD133 were inhibited by artemilavanin F. Downregulation of epithelial-mesenchymal transition (EMT) markers such as N-cadherin and Oct-4 indicated the potential of artemilavanin F in prevention of metastasis.Copyright © 2023 Elsevier Ltd. All rights reserved.